头孢地尔在治疗广泛耐药铜绿假单胞菌感染中的活性：CANWARD，2007 年至 2019 年。
Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019.
机构信息
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitobagrid.21613.37, Winnipeg, Manitoba, Canada.
Clinical Microbiology, Diagnostic Services, Shared Health, Winnipeg, Manitoba, Canada.
出版信息
Microbiol Spectr. 2022 Aug 31;10(4):e0172422. doi: 10.1128/spectrum.01724-22. Epub 2022 Jun 27.
Abstract
Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019). Overall, 98.3% of isolates remained cefiderocol susceptible (MIC, ≤4 μg/mL), including 97.4% of extensively drug-resistant (XDR) (= 235) and 97.9% of multidrug-resistant (MDR) (= 771) isolates. Most isolates testing not susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam remained susceptible to cefiderocol. data suggest that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa. After testing cefiderocol against a large collection of clinical isolates of highly antimicrobial-resistant Pseudomonas aeruginosa, we report that cefiderocol is active versus 97.4% of extensively drug-resistant (XDR) and 97.9% of multidrug-resistant (MDR) ( = 771) isolates. These data show that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa.
摘要
头孢他啶-阿维巴坦、头孢吡肟-他唑巴坦和亚胺培南-雷巴坦耐药的铜绿假单胞菌临床分离株对头孢地尔进行了肉汤微量稀释法评估，这些分离株来自 CANWARD 研究（2007 年至 2019 年），共 1050 株。总体而言，98.3%的分离株对头孢地尔仍保持敏感（MIC，≤4μg/mL），包括 97.4%的广泛耐药（XDR）（=235）和 97.9%的多重耐药（MDR）（=771）分离株。大多数对头孢他啶-阿维巴坦、头孢吡肟-他唑巴坦和亚胺培南-雷巴坦药敏试验结果显示不敏感的分离株仍对头孢地尔敏感。这些数据表明，头孢地尔可能是治疗 MDR 和 XDR 铜绿假单胞菌感染的一种选择。我们对大量耐多种抗菌药物的铜绿假单胞菌临床分离株进行了头孢地尔药敏试验，结果显示头孢地尔对 97.4%的广泛耐药（XDR）（=235）和 97.9%的多重耐药（MDR）（=771）分离株仍具有活性。这些数据表明，头孢地尔可能是治疗 MDR 和 XDR 铜绿假单胞菌感染的一种选择。
相似文献
1
Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019.头孢地尔在治疗广泛耐药铜绿假单胞菌感染中的活性：CANWARD，2007 年至 2019 年。
Microbiol Spectr. 2022 Aug 31;10(4):e0172422. doi: 10.1128/spectrum.01724-22. Epub 2022 Jun 27.
2
Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.头孢洛扎他唑巴坦、头孢他啶-阿维巴坦和头孢地尔在德国一所大学医院分离的多重耐药铜绿假单胞菌中的抗菌活性。
Microbiol Spectr. 2022 Oct 26;10(5):e0169722. doi: 10.1128/spectrum.01697-22. Epub 2022 Oct 3.
3
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.头孢地尔肟、亚胺培南/雷巴他定、头孢吡肟/他唑巴坦和头孢吡肟/齐多夫定对头孢他啶/他唑巴坦和头孢噻肟/阿维巴坦耐药铜绿假单胞菌的活性。
J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241.
4
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.同情用药项目中头孢地尔治疗多重耐药和碳青霉烯类耐药铜绿假单胞菌感染患者的疗效。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0019423. doi: 10.1128/aac.00194-23. Epub 2023 Jun 22.
5
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.在体外研究中，头孢地尔、头孢他唑巴坦/他唑巴坦、头孢他啶/阿维巴坦和其他比较药物对耐亚胺培南铜绿假单胞菌和鲍曼不动杆菌以及嗜麦芽窄食单胞菌的活性，这些细菌均与台湾的血流感染有关。
J Antimicrob Chemother. 2019 Feb 1;74(2):380-386. doi: 10.1093/jac/dky425.
6
Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021).朝着标准化的抗微生物药物耐药性定义迈进：比较难处理的耐药性 (DTR) 与多重耐药 (MDR) 铜绿假单胞菌临床分离株的抗微生物药物敏感性特征 (CANWARD，2016-2021 年)。
Diagn Microbiol Infect Dis. 2024 Feb;108(2):116130. doi: 10.1016/j.diagmicrobio.2023.116130. Epub 2023 Nov 17.
7
In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.2008-2016 年，作为 CANWARD 研究的一部分，在加拿大各地收集了包括 MDR 和 XDR 分离株在内的对非敏感的铜绿假单胞菌临床分离株，评估头孢洛扎/他唑巴坦的体外活性。
J Antimicrob Chemother. 2018 Mar 1;73(3):703-708. doi: 10.1093/jac/dkx468.
8
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、亚胺培南/雷巴坦、美罗培南/沃巴坦和对照药物对皮肤软组织感染患者分离的铜绿假单胞菌的抗菌活性。
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
9
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).新型β-内酰胺/β-内酰胺酶抑制剂组合对来自美国医疗中心的铜绿假单胞菌分离株的比较活性（2020 - 2021年）
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
10
Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program.头孢地尔在 2020 年 SENTRY 抗菌监测计划中对美国和欧洲革兰氏阴性临床分离株的活性。
Microbiol Spectr. 2022 Apr 27;10(2):e0271221. doi: 10.1128/spectrum.02712-21. Epub 2022 Mar 9.
引用本文的文献
1
Investigational antibiotic cefepime/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report.研究性抗生素头孢吡肟/齐德巴坦作为治疗一名由广泛耐药铜绿假单胞菌引起的小儿难治性脓胸的治疗选择：病例报告
Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1349-1355. doi: 10.1007/s10096-025-05106-8. Epub 2025 Mar 18.
2
In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022.新型β-内酰胺/β-内酰胺酶抑制剂组合及头孢地尔对2022年在瑞士收集的耐碳青霉烯类假单胞菌临床分离株的体外活性
Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):571-585. doi: 10.1007/s10096-024-04994-6. Epub 2024 Dec 20.
3
Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-Resistant Strains: Influence of Bacterial Inoculum.不同方法测定头孢地尔对碳青霉烯耐药菌株体外活性的比较：细菌接种量的影响
Antibiotics (Basel). 2024 Jul 18;13(7):663. doi: 10.3390/antibiotics13070663.
4
Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.亚胺培南/瑞来巴坦对革兰氏阴性杆菌的全球耐药性：系统评价和荟萃分析
Curr Ther Res Clin Exp. 2023 Oct 28;100:100723. doi: 10.1016/j.curtheres.2023.100723. eCollection 2024.
5
activity of cefiderocol against demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors.头孢地尔对表现出对新型β-内酰胺/β-内酰胺酶抑制剂产生进化抗性的活性。 （原英文句子似乎不太完整通顺，翻译可能会稍显生硬，你可检查下原文是否准确）
JAC Antimicrob Resist. 2023 Oct 3;5(5):dlad107. doi: 10.1093/jacamr/dlad107. eCollection 2023 Oct.
6
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.用头孢地尔治疗重症患者耐多药病原体引起的感染：证据综述
Ann Intensive Care. 2023 Jun 15;13(1):52. doi: 10.1186/s13613-023-01146-5.
7
Machine Learning Techniques for Antimicrobial Resistance Prediction of from Whole Genome Sequence Data.基于全基因组序列数据的微生物耐药性预测的机器学习技术。
Comput Intell Neurosci. 2023 Mar 1;2023:5236168. doi: 10.1155/2023/5236168. eCollection 2023.
本文引用的文献
1
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant (DTR-P) infections.头孢地尔同情用药治疗难治性耐药（DTR-P）感染的真实生活经验。
JAC Antimicrob Resist. 2021 Dec 11;3(4):dlab188. doi: 10.1093/jacamr/dlab188. eCollection 2021 Dec.
2
Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019.2014 年至 2019 年连续五年跨国 SIDERO-WT 监测研究中革兰氏阴性病原体对头孢地尔的敏感性。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0199021. doi: 10.1128/AAC.01990-21. Epub 2021 Nov 22.
3
Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report.新冠肺炎患者慢性左肺胸膜脓胸经头孢地尔长期成功治疗：一例病例报告
J Glob Antimicrob Resist. 2021 Dec;27:157-159. doi: 10.1016/j.jgar.2021.09.005. Epub 2021 Sep 22.
4
A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR .同情用药使用头孢地尔治疗由广泛耐药菌引起的骨髓炎。
JAC Antimicrob Resist. 2021 Jun 15;3(Suppl 1):i18-i20. doi: 10.1093/jacamr/dlab054. eCollection 2021 Jun.
5
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.头孢地尔与大剂量延长输注美罗培南治疗革兰阴性菌医院获得性肺炎（APEKS-NP）：一项随机、双盲、3期、非劣效性试验。
Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.
6
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
7
Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.头孢他啶美罗培南复方制剂（cefiderocol）对多重耐药革兰氏阴性菌的活性。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01582-20.
8
42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.从加拿大医院采集的 42936 种病原体：CANWARD 监测研究十年（2007-2016 年）的结果。
J Antimicrob Chemother. 2019 Aug 1;74(Suppl 4):iv5-iv21. doi: 10.1093/jac/dkz283.
9
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
10
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.头孢地尔优于亚胺培南西司他丁钠治疗革兰氏阴性尿路病原体引起的复杂性尿路感染：一项 2 期、随机、双盲、非劣效性试验。
Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.
Zotero 插件